Table 1.

Characteristics of Patients With Metastatic Neuroblastoma Lacking MYCN Gene Amplification

Characteristic	Training Cohort (age at diagnosis, months)				Validation Cohorts (age at diagnosis, months)
	CCG				GPOH		COG
	< 18 (n = 39)		≥ 18 (n = 94)		≥ 18 (n = 39)		≥ 18 (n = 52)
	No.	%	No.	%	No.	%	No.	%
Age at diagnosis, months
Mean	9.3	53.6	56	55.9
Range	0.1-17.3		18.2-151		18.4-182		19.5-186
COG risk stratification	Intermediate*		High		High		High
INPC classification
Favorable	34	87	2	2	3	8	3	6
Unfavorable	5	13	91	97	34	87	42	81
Unknown	0	0	1	1	2	5	7	13
Clinical trials	323P, 3881		323P, 321-2, 321-3, 3891		NB90, NB95, NB97, NB2004		A3973†
5-year EFS rate, %	95		23		34		31
95% CI, %	81 to 99		15 to 32		19 to 50		19 to 44
5-year OS rate, %	95		35		50		38
95% CI, %	81 to 99		25 to 44		32 to 66		23 to 54

Abbreviations: CCG, Children's Cancer Group; COG, Children's Oncology Group; EFS, event-free survival; GPOH, German Society for Pediatric Oncology-Hematology (Gesellschaft für Paediatrische Onkologie und Haematologie); INPC, International Neuroblastoma Pathology Classification; OS, overall survival.

^*Patients age > 12 months were classified as high risk and treated accordingly per CCG guidelines. On the basis of current COG guidelines, four of 12 patients diagnosed at 12 to 18 months of age with unfavorable tumor histology would be considered high risk.

^†Three patients were treated on ANBL0532.